Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11538 |
Hck-IN-1
|
HIV Protease; Src; Hck | Angiogenesis; Microbiology/Virology; Proteases/Proteasome; Tyrosine Kinase/Adaptors |
Hck-IN-1 是二苯基吡唑啉化合物,选择性的 Nef 依赖性 Hck 抑制剂。它是广泛的 HIV-1 Nef 直接拮抗剂,对于野生型 HIV-1 复制的IC50为 100-300 nM。它结合口袋残基 Asn126,具有抗逆转录病毒活性。 | |||
T13186 |
TL02-59
|
Apoptosis; Src; Hck | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
TL02-59 是 Src 家族激酶中 Fgr 的特异性抑制剂 (IC50 = 0.03 nM)。 TL02-59 抑制 Lyn 和 Hck,IC50 分别为 0.1 nM 和 160 nM。 TL02-59 有效抑制急性髓性白血病细胞的生长。 | |||
T40594 |
iHCK-37
iHCK-37,ASN05260065 |
||
iHCK-37 (ASN05260065) is a high-potency, selective inhibitor of Hck with a Ki value of 0.22 μM. It effectively inhibits HIV-1 viral replication, exhibiting an EC50 value of 12.9 μM. Primarily employed in chronic myeloid leukemia (CML) research, iHCK-37 demonstrates promising potential for studying and understanding this disease. | |||
T2415 |
PP121
|
Apoptosis; VEGFR; Bcr-Abl; PDGFR; Src; mTOR; Hck | Angiogenesis; Apoptosis; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
PP121是一种多靶点激酶抑制剂,抑制 PDGFR、Hck、mTOR、VEGFR2、Src、Abl、DNK-PK 的 IC50值分别为2、8、10、12、14、18、60 nM。 | |||
T72918 |
JNJ-49095397
RV568 |
||
JNJ-49095397 (RV568) 是一种吸入性窄谱激酶抑制剂 (NSKI),可抑制p38 MAPK 的 α 和 γ 亚型。JNJ-49095397 还抑制SRCkinase 家族,特别是造血激酶(HCK),显示出强大的抗炎作用,可用于慢性阻塞性肺疾病 (COPD) 和哮喘的研究。 | |||
T61793 |
HIV-IN-6
|
HIV Protease | Microbiology/Virology; Proteases/Proteasome |
HIV-IN-6 是一种 HIV 病毒抑制剂,可抑制HIV 病毒的复制。HIV-IN-6 具有抗HIV 病毒的活性,通过靶向与病毒 Nef 蛋白相互作用的 Src 家族激酶 (SFK) (如 Hck) 而起作用。 | |||
T6093 |
AZD-7762
AZD7762 |
Chk | Cell Cycle/Checkpoint |
AZD-7762 是一种有效的 ATP 竞争性的细胞周期检测点激酶抑制剂,抑制 Chk1的 IC50为 5 nM。 | |||
T6217 |
LFM-A13
|
PLK; JAK; BTK | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
LFM-A13 是一种 BTK,JAK2,PLK 有效抑制剂,可抑制 BTK、Plx1 和 PLK3 的活性,IC50分别为 2.5、10 和 61 μM。 | |||
T2640 |
Rebastinib
DCC2036,DCC 2036,DCC-2036 |
Apoptosis; FLT; Bcr-Abl; Src | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Rebastinib (DCC-2036) 是一种口服有效的,非 ATP 竞争性的 Bcr-Abl 抑制剂,作用于 Abl1WT 和 Abl1T315I,IC50分别为 0.8 nM 和 4 nM,还抑制 LYN、SRC、HCK、FGR、FLT3、KDR 和 Tie-2,对 c-Kit 的活性低。Rebastinib 对 Angiopoietin2-Tie2通路具有抑制作用。 | |||
T79516 |
BT424
|
Src | Angiogenesis; Tyrosine Kinase/Adaptors |
BT424是一种特异性HCK抑制剂,能够调节体外巨噬细胞的活化及自噬,并在UUO模型中改善炎症和肾纤维化。 | |||
T13156 |
TG 100572
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively). | |||
T38965 |
EPQpYEEIPIYL
|
||
EPQpYEEIPIYL, a phosphopeptide, is a ligand for the Src homology 2 (SH2) domain. It activates members of the Src family, such as Lck, Hck, and Fyn, through the binding interaction with SH2 domains. | |||
T13157L | TG 100801 Hydrochloride | VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
TG 100801 Hydrochloride is a prodrug to treat age-related macular degeneration. TG 100572 is a inhibitor of multi-targeted kinase(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, | |||
T13156L |
TG 100572 Hydrochloride
|
VEGFR; FGFR; PDGFR; Src | Angiogenesis; Tyrosine Kinase/Adaptors |
TG 100572 Hydrochloride 是一种多靶点激酶抑制剂,能够抑制受体酪氨酸激酶和Src 激酶。 | |||
T13186L |
TL02-59 dihydrochloride
|
Src | Angiogenesis; Tyrosine Kinase/Adaptors |
TL02-59 dihydrochloride is an orally active inhibitor of Src-family kinase Fgr (IC50: 0.03 nM). |